Published in J Headache Pain on January 24, 2008
Family studies to find rare high risk variants in migraine. J Headache Pain (2017) 0.75
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 6.61
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med (2004) 4.39
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology (2007) 3.43
Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia (2000) 3.32
Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet (1998) 2.98
Clinical update: diagnosis and treatment of essential tremor. Lancet (2007) 2.66
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 1.54
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia (2004) 1.45
beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther (2006) 1.31
Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia (1997) 1.30
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics (2002) 1.14
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia (2004) 1.13
Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia (2005) 1.11
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics (2006) 1.02
G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther (2007) 0.98
Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.97
Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol (1995) 0.95
Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol (2005) 0.95
The discovery of a new drug class for the acute treatment of migraine. Headache (2007) 0.93
Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos (1996) 0.91
Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics (2005) 0.91
Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther (2005) 0.88
Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache (2004) 0.88
Maximum effect of triptans in migraine? A comment. Cephalalgia (2008) 0.88
Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie (2004) 0.88
Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol (2003) 0.88
Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia (1986) 0.87
Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol (1998) 0.86
Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs (1989) 0.86
311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia (1996) 0.86
Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology (2005) 0.86
The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther (2006) 0.86
Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci (2006) 0.85
The impact of pharmacogenetics for migraine. Eur J Pharmacol (2001) 0.85
Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol (1986) 0.85
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther (2000) 0.84
5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache (1998) 0.83
Rizatriptan: an update of its use in the management of migraine. Drugs (2002) 0.83
Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache (2006) 0.81
Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet (1998) 0.80
Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain (2007) 0.79
Almotriptan: a review of its use in migraine. Drugs (2002) 0.78
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia (2007) 0.78
Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein beta3 subunit gene (GNB3). Clin Pharmacol Ther (2003) 0.77
Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. J Headache Pain (2006) 0.77
Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects. Arch Neurol (1985) 0.76
The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan. Headache (2007) 0.76
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol (2010) 1.71
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics (2002) 1.14
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol (2006) 1.13
Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol (2011) 0.96
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol (2005) 0.95
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol (2004) 0.95
The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg (2006) 0.94
A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics (2013) 0.93
Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain (2008) 0.92
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol (2006) 0.87
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther (2002) 0.87
In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol Toxicol (2003) 0.86
A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia (2007) 0.86
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol (2011) 0.85
Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. Eur J Clin Pharmacol (2006) 0.84
Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol Appl Pharmacol (2007) 0.82
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther (2002) 0.82
A Comprehensive Review of Drug-Drug Interactions with Metformin. Clin Pharmacokinet (2015) 0.81
Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. Br J Clin Pharmacol (2015) 0.81
Expressing effects of osteoporosis interventions in terms of postponing of fractures. Eur J Clin Pharmacol (2002) 0.81
Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. Nord J Psychiatry (2008) 0.78
The Pharmacogenetics of Tramadol. Clin Pharmacokinet (2015) 0.78
Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain (2015) 0.78
Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. Eur J Clin Pharmacol (2010) 0.77
Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Basic Clin Pharmacol Toxicol (2005) 0.77
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics (2013) 0.77
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol (2012) 0.77
Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. Ther Drug Monit (2014) 0.77
Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark. Basic Clin Pharmacol Toxicol (2004) 0.76
Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol (2015) 0.76
No evidence for taxane/platinum pharmacogenetic markers: just lack of power? J Clin Oncol (2008) 0.75
[The use of the monoamine oxidase inhibitor isocarboxazide in treatment-resistant depression]. Ugeskr Laeger (2015) 0.75
Letter from the editor. Basic Clin Pharmacol Toxicol (2011) 0.75
The BCPT 2016 prize to Jan Alexander, Norway. Basic Clin Pharmacol Toxicol (2017) 0.75
The Impact of Serum Drug Concentration on the Efficacy of Imipramine, Pregabalin and their Combination in Painful Polyneuropathy. Clin J Pain (2017) 0.75
Letter from the editor. Basic Clin Pharmacol Toxicol (2009) 0.75
Letter from the Editor. Basic Clin Pharmacol Toxicol (2017) 0.75
Letter from the editor. Basic Clin Pharmacol Toxicol (2012) 0.75
[Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review]. Ugeskr Laeger (2002) 0.75
Letter from the editor. Basic Clin Pharmacol Toxicol (2013) 0.75
BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany. Basic Clin Pharmacol Toxicol (2013) 0.75
Professor Thue W. Schwartz is the BCPT Nordic Prize Winner 2017 in Basic & Clinical Pharmacology & Toxicology. Basic Clin Pharmacol Toxicol (2017) 0.75
BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology for 2011 to Pertti J. Neuvonen. Basic Clin Pharmacol Toxicol (2012) 0.75
[Antibiotics and overweight]. Ugeskr Laeger (2005) 0.75
Professor Jens Sølver Schou 10 October 1929-8 March 2017. Basic Clin Pharmacol Toxicol (2017) 0.75
Letter from the Editor. Basic Clin Pharmacol Toxicol (2017) 0.75
[Drug induced hepatotoxicity--don't forget herbals and dietary supplements!]. Ugeskr Laeger (2011) 0.75
[Clinical pharmacology--important events in 2003. The Danish Society of Clinical Pharmacology]. Ugeskr Laeger (2004) 0.75
Professor Olavi Pelkonen is the 2014 BCPT Nordic Prize Winner in Basic and Clinical Pharmacology and Toxicology. Basic Clin Pharmacol Toxicol (2015) 0.75
[Clinical pharmacology 2001--important events. The Danish Society of Clinical Pharmacology]. Ugeskr Laeger (2002) 0.75
Quantification of morphine, morphine 6-glucuronide, buprenorphine, and the enantiomers of methadone by enantioselective mass spectrometric chromatography in whole blood. Forensic Sci Med Pathol (2015) 0.75